HDAC9 and neoplasm: Although many HDAC inhibitors have shown strong anti-tumor efficacies in preclinical studies, and four have already been approved by the United States Food and Drug Administration (FDA), all currently existing HDAC inhibitors have been found to be associated with side effects linked to their concomitant inhibitory activities against multiple HDACs [141, 142].